Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

Cited In for PubMed (Select 16500560)


Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin.

Labos C, Nguyen V, Giannetti N, Huynh T.

Open Cardiovasc Med J. 2014 Sep 15;8:76-82. doi: 10.2174/1874192401408010076. eCollection 2014.


Dietary sodium restriction below 2 g per day predicted shorter event-free survival in patients with mild heart failure.

Song EK, Moser DK, Dunbar SB, Pressler SJ, Lennie TA.

Eur J Cardiovasc Nurs. 2014 Dec;13(6):541-8. doi: 10.1177/1474515113517574. Epub 2013 Dec 23.


Electronically monitored medication adherence predicts hospitalization in heart failure patients.

Riegel B, Knafl GJ.

Patient Prefer Adherence. 2013 Dec 5;8:1-13. doi: 10.2147/PPA.S54520. eCollection 2013.


The CopenHeartSF trial--comprehensive sexual rehabilitation programme for male patients with implantable cardioverter defibrillator or ischaemic heart disease and impaired sexual function: protocol of a randomised clinical trial.

Johansen PP, Zwisler AD, Hastrup-Svendsen J, Frederiksen M, Lindschou J, Winkel P, Gluud C, Giraldi A, Steinke E, Jaarsma T, Berg SK.

BMJ Open. 2013 Nov 25;3(11):e003967. doi: 10.1136/bmjopen-2013-003967.


Surgical treatment of functional mitral regurgitation in dilated cardiomyopathy.

Al-Amri HS, Al-Moghairi AM, El Oakley RM.

J Saudi Heart Assoc. 2011 Jul;23(3):125-34. doi: 10.1016/j.jsha.2011.04.001. Epub 2011 Apr 16. Review.


Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches.

Koniari K, Parissis J, Paraskevaidis I, Anastasiou-Nana M.

Eur Heart J Acute Cardiovasc Care. 2012 Sep;1(3):256-68. doi: 10.1177/2048872612457044.


Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).

Goldberg RJ, Gurwitz JH, Saczynski JS, Hsu G, McManus DD, Magid DJ, Smith DH, Go AS; CVRN PRESERVE HF Investigators.

Am J Cardiol. 2013 May 1;111(9):1324-9. doi: 10.1016/j.amjcard.2013.01.276. Epub 2013 Feb 1.


Biomarker changes during acute heart failure treatment.

Boyer B, Hart KW, Sperling MI, Lindsell CJ, Collins SP.

Congest Heart Fail. 2012 Mar-Apr;18(2):91-7. doi: 10.1111/j.1751-7133.2011.00256.x. Epub 2011 Oct 17.


Perceptions and experiences of heart failure patients and clinicians on the use of mobile phone-based telemonitoring.

Seto E, Leonard KJ, Cafazzo JA, Barnsley J, Masino C, Ross HJ.

J Med Internet Res. 2012 Feb 10;14(1):e25. doi: 10.2196/jmir.1912.


Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study.

McManus DD, Lyass A, Ingelsson E, Massaro JM, Meigs JB, Aragam J, Benjamin EJ, Vasan RS.

Obesity (Silver Spring). 2012 Sep;20(9):1882-6. doi: 10.1038/oby.2011.32. Epub 2011 Feb 24.


Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation.

Cappola TP, Matkovich SJ, Wang W, van Booven D, Li M, Wang X, Qu L, Sweitzer NK, Fang JC, Reilly MP, Hakonarson H, Nerbonne JM, Dorn GW 2nd.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2456-61. doi: 10.1073/pnas.1017494108. Epub 2011 Jan 19.


Adherence to the low-sodium diet plays a role in the interaction between depressive symptoms and prognosis in patients with heart failure.

Song EK.

J Cardiovasc Nurs. 2009 Jul-Aug;24(4):299-305; quiz 306-7. doi: 10.1097/JCN.0b013e3181a6a1e5.


Survival and cardioprotective benefits of long-term blueberry enriched diet in dilated cardiomyopathy following myocardial infarction in rats.

Ahmet I, Spangler E, Shukitt-Hale B, Joseph JA, Ingram DK, Talan M.

PLoS One. 2009 Nov 19;4(11):e7975. doi: 10.1371/journal.pone.0007975.


Development, psychometric testing, and revision of the Atlanta Heart Failure Knowledge Test.

Reilly CM, Higgins M, Smith A, Gary RA, Robinson J, Clark PC, McCarty F, Dunbar SB.

J Cardiovasc Nurs. 2009 Nov-Dec;24(6):500-9. doi: 10.1097/JCN.0b013e3181aff0b0.


Management of end-stage heart failure: a perspective on the Arab Gulf states.

Al Habeeb W, Stewart GC, Mudge GH.

Ann Saudi Med. 2009 Nov-Dec;29(6):460-6. doi: 10.4103/0256-4947.57169. Review.


Baseline differences in the HF-ACTION trial by sex.

PiƱa IL, Kokkinos P, Kao A, Bittner V, Saval M, Clare B, Goldberg L, Johnson M, Swank A, Ventura H, Moe G, Fitz-Gerald M, Ellis SJ, Vest M, Cooper L, Whellan D; HF-ACTION Investigators.

Am Heart J. 2009 Oct;158(4 Suppl):S16-23. doi: 10.1016/j.ahj.2009.07.012.


Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.

Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr.

J Clin Pharmacol. 2009 Jun;49(6):668-73. doi: 10.1177/0091270009336233. Epub 2009 Apr 24.


Family caregiver outcomes in heart failure.

Pressler SJ, Gradus-Pizlo I, Chubinski SD, Smith G, Wheeler S, Wu J, Sloan R.

Am J Crit Care. 2009 Mar;18(2):149-59. doi: 10.4037/ajcc2009300.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk